Nintedanib
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2421 publications
Pharmacological advances of alkaloids from Traditional Chinese Medicine against pulmonary fibrosis: focus on anti-inflammatory mechanisms.
Journal: Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
Published: October 30, 2026
Therapeutic advances in pulmonary fibrosis.
Journal: Therapeutic advances in respiratory disease
Published: October 24, 2026
Reply: Comparative Clinical Outcomes of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis: A Five-Year Real-Life Study.
Journal: Thoracic research and practice
Published: October 21, 2026
Nintedanib in progressive fibrosing hypersensitivity pneumonitis: Real-world effects on lung function and survival.
Journal: Therapeutic advances in respiratory disease
Published: October 14, 2026
Nintedanib-induced Glomerular Microangiopathy after Long-term Nintedanib Administration Presenting with Nephrotic Syndrome.
Journal: Internal medicine (Tokyo, Japan)
Published: October 14, 2026
Targeting fibroblast activation suppresses chemotherapy-induced pro-invasive remodeling of the extracellular matrix.
Journal: bioRxiv : the preprint server for biology
Published: October 01, 2026
Tofacitinib in rheumatoid arthritis-associated interstitial lung disease: immunomodulation and antifibrotic therapy as complementary strategies?
Journal: Respiratory medicine
Published: September 26, 2026
Parameters predicting mortality in antifibrotic-treated IPF patients: mMRC, CPI, TLCO, FVC, GAP.
Journal: Biomarkers in medicine
Published: September 25, 2026
Multi-omics reveals a monocyte-macrophage-fibroblast axis in post-COVID-19 fibroinflammatory lung remodelling.
Journal: bioRxiv : the preprint server for biology
Published: September 24, 2026
The emerging role of PDE4 inhibitors for the treatment of pulmonary fibrosis.
Journal: Expert review of clinical pharmacology
Published: September 22, 2026
Comparative Clinical Outcomes of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis: A Five-year Real-life Study.
Journal: Thoracic research and practice
Published: September 04, 2026
Last Updated: 11/08/2026